Myriad Logo
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • 2022 Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us
  • About Myriad
    • Events & Presentations
    • Corporate Governance
    • Myriad Milestones
    • 2022 Investor Day Presentations
  • News
    • Financial
    • Corporate
    • Product
    • Pipeline
  • Financial Reporting
    • GAAP to Non-GAAP Reconciliation
    • Latest Earnings Release
      • Earnings Presentation
    • SEC Filings
    • Quarterly & Annual Reports
    • Investor FAQs
      • Email Alerts Subscription
  • Contact Us

News Releases

Nov 10, 2022
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
Products
Nov 01, 2022
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
Pipeline
Aug 25, 2022
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer
Pipeline
Jun 23, 2022
Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
Pipeline
May 03, 2022
Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions
Pipeline
Nov 22, 2021
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
Pipeline
Aug 02, 2021
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Pipeline
May 19, 2021
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
Pipeline
Mar 24, 2021
Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan
Products
Mar 02, 2021
Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services
Pipeline
Feb 12, 2021
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer
Pipeline
Jan 08, 2021
Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®
Products
Dec 11, 2020
New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations
Pipeline
Nov 16, 2020
Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
Pipeline
Nov 11, 2020
New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis
Pipeline
Next page
  • Payers
    • Overview
  • Investors
    • Investor Relations
    • Events & Presentations
    • Investor Day
  • News
    • Press Releases
    • Email Alerts Subscription
    • Myriad Genetics Blog
  • Careers
    • Joining the Team
Myriad Logo

Health. Illuminated.

  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Language Assistance
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.